# Zanubrutinib in Patients With IgG4-Related Disease

> **NCT04602598** · PHASE2 · COMPLETED · sponsor: **Matthew C. Baker** · enrollment: 10 (actual)

## Conditions studied

- IgG4 Related Disease

## Interventions

- **DRUG:** Zanubrutinib 80 MG

## Key facts

- **NCT ID:** NCT04602598
- **Lead sponsor:** Matthew C. Baker
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-01
- **Primary completion:** 2025-02-11
- **Final completion:** 2025-04-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04602598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04602598, "Zanubrutinib in Patients With IgG4-Related Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04602598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*